Sweden and Denmark are among the countries in the world with the highest type-1 diabetes prevalence. Both countries have a long tradition of excellent research and treatment, and with the new joint diabetes project DiaUnion, supported by the EU’s Interreg program, we are bridging research among the two countries to jointly put in an extra effort to fight the deadly disease. The DiaUnion project strengthens and develops Greater Copenhagen’s life science cluster Medicon Valley’s position as one of Europe’s leading centers for autoimmune diabetes research.
Earlier this year, the Capital Region of Denmark and Region Skåne in Sweden, signed a letter of intent to strengthen the Greater Copenhagen regional cooperation in, among other things, health. As a concrete follow-up to that statement, both regions, Lund University, Steno Diabetes Center Copenhagen and the Danish-Swedish life science cluster organization, Medicon Valley Alliance (MVA), have proposed a targeted approach to autoimmune diabetes, which will strengthen, over the next two years, the research aimed at developing new treatments for the region’s diabetic patients. Half of the project is funded by an EU grant of € 500,000, but the other half is funded by the Capital Region of Denmark, Region Skåne and Steno Diabetes Center.
The project will fund both closer cross-border research collaboration and support a joint Danish-Swedish effort targeted prevention and treatment. The ambition is also to explore opportunities for educational cooperation between the region’s universities, and a patient mobility agreement whereby patients in the region will be offered the optimal treatment, whether it is offered in Region Skåne or the Capital Region of Denmark. The project thus fetches inspiration from the long-standing ReproUnion project, where the involuntarily childless have the opportunity to benefit from the different expertise and specialties on both sides of the Sound.
– Diabetes is a common disease in the future. As responsible politicians, we need to find the best solutions, and here it is obvious that we unite forces across the Danish-Swedish border and together use common expertise to become more skilled and better at finding the right treatment for people with diabetes, says the regional council chairman in the Capital Region of Denmark, Sophie Hæstorp Andersen.
The enthusiasm is shared on the Swedish side of the Sound.
– Region Skåne fully supports the project. We regard our share of the funding as a strategic investment in both better research and better treatment services, says Regional Council Chairman for Region Skåne Carl Johan Sonesson, who emphasizes that a significant part of the research will take place in hospitals in Skåne. Region of Skåne looking forward to working more closely with the neighbors in Denmark
– In the Greater Copenhagen region, we stand on the shoulders of excellent and internationally recognized research when it comes to screening, genetics and immunology in type 1 diabetes. Now we pool knowledge and resources further so that we can maintain and expand the current leadership position, says Petter Hartman, CEO of the Medicon Valley Alliance.
– On both sides of the Sound we have fantastic competences in diabetes research that complement each other. By gathering these we can achieve results that neither of us could have achieved individually. At the same time, we are creating a research center that is incredibly strong internationally, says Finn Stensbjerg Kristensen, from T1com, who initiated the project, and whose purpose is to support the development of better treatment methods for type 1 diabetes.
– The ambition is a paradigm shift in our understanding of the pathophysiology of type 1 diabetes. We expect that the research will contribute knowledge to develop new strategies for more targeted intervention at various stages of the disease process. This will have a huge impact on people living with, or at risk of developing, type 1 diabetes as well as their families, says Flemming Pociot, Professor, Chief Physician, Steno Diabetes Center in Copenhagen.
– Based on the underlying mechanisms such as 1 diabetes shares with other autoimmune diseases the project will bridge these. The project seeks to explain why celiac disease affects 10% and thyroid inflammation (a form of trauma) affects up to 30% of all children with type-1 diabetes, says Åke Lernmark, professor at Lund University.
Daniel Agardh, consultant, expert in celiac disease and adjunct professor at Lund University, emphasizes that the link between celiac disease, type-1 diabetes and other autoimmune diseases carries a huge potential for the development of new drugs and therapies that have so far only been realized to a limited extent.
The project starts on January 1, 2020 and runs until August 2020. The project’s total budget is 1,000,000 euros and is funded, besides Interreg, by the Capital Region of Denmark, Region Skåne and Steno Diabetes Center Copenhagen.
Facts about Type 1 diabetes:
Type 1 diabetes is an autoimmune disease where the body’s immune system erroneously destroys its own insulin-producing cells. Insulin is a hormone you cannot live without, as it enables the transport of nutrients in the form of glucose into the cells, and you will die if you do not receive insulin artificially. In contrast to type 2 diabetes, the disease is not lifestyle-related can therefore not be cured or prevented through healthier living. Type 1 diabetes occurs randomly, most often in childhood and adolescence, and if you first get the disease, you have to live with it for the rest of your life. Sweden and Denmark are among the countries in the world with the highest incidence and prevalence of type 1 diabetes. In Sweden, 2 children are diagnosed every day and approx. 50,000 people have the disease. In Denmark, the figures are similarly high: About 30,000 Danes have type 1 diabetes, of whom 4,000 are children and adolescents.
Living with type 1 diabetes requires attention around the clock in a constant and difficult balancing of dietary intake, activity, blood glucose control (even at night) and insulin injection. With the existing treatment options, it is an impossible challenge to balance all variables perfectly, it is simply too complicated, and no other illness requires so much of the patient on a daily basis. For this reason, the national treatment targets are not reached, resulting in disabling complications and mortality.
Contact for more information:
Press contact Capital Region of Denmark via Region Hovedstadens press guard on +45 70 20 95 88
Press contact Region Skåne: Peter J Olsson Senior political adviser (M) Region Skåne + (46) 044-309 3020 Tel: + (46) 070-4487170 email@example.com
Press contact Medicon Valley Alliance: Petter Hartman CEO +45 23 71 55 77 firstname.lastname@example.org